170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors. - Jeger, S.; Schönborn-Kellenberger, O.; De Winter, H.; Steeghs, N.; Gort, E.; Gomez-Roca, C.; Stavropoulou, V.; Kenefeck, R.; Fernandez, E.; Ji, H.; Marchand, C.; Legenne, P.; et al. (Annals of Oncology, 2021)